The Role of Mucosal Immunity in the Control of Respiratory Infectious Diseases
DOI:
https://doi.org/10.61173/0s1j4z92Keywords:
Mucosal immunity, respiratory infectious diseases, secretory IgAAbstract
Respiratory infectious pathogens such as influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 persist as significant threats to global health. Most of the pathogens come in through the respiratory mucosa, with the local immune mechanisms as the first line of defense. Here, we explore the role of mucosal immunity, such as secretory immunoglobulin A (sIgA), tissue-resident memory T cells (TRM), and inducible bronchus-associated lymphoid tissue (iBALT), in the management of respiratory infections in this research. The mechanistic part illustrates how mucosal vaccination achieves these reactions by protecting within the zone of pathogen entry. There is now experimental data on live attenuated influenza vaccination (LAIV), studies on preclinical SARS-CoV-2 mucosal vaccine, and early human trials that demonstrate the possible role of mucosal vaccination in limiting viral replication and transmission. But the translational challenge is still with various aspects, such as uniform mucosal immune correlates, heterogeneity in formulation and delivery, and regulatory obstacles. Mucosal vaccines provide a compelling complement to systemic immunization but remain challenging to implement. By acting via both systemic and local immunity, these vaccines are likely to play a role in comprehensive respiratory disease control as well as preparing populations for pandemics. These results highlight the necessity for mucosal immunity to be considered as a pillar of future vaccine development and public health policy framework.
References
[1] Neutra, M. R., & Kozlowski, P. A. (2006). Mucosal vaccines: The promise and the challenge. Nature Reviews Immunology, 6(2), 148–158. https://doi.org/10.1038/nri1777
[2] Holmgren, J., & Czerkinsky, C. (2005). Mucosal immunity and vaccines. Nature Medicine, 11(4 Suppl), S45–S53. https:// doi.org/10.1038/nm1213
[3] Greaney, A. J., et al. (2024). Mucosal immunity in COVID-19: A comprehensive review. Frontiers in Immunology, 15, 1433452. https://doi.org/10.3389/fimmu.2024.1433452
[4] Halle, S., et al. (2009). Induced BALT serves as a general priming site for T cells. Proceedings of the National Academy of Sciences, 106(33), 13987–13992. https://doi.org/10.1073/ pnas.0904846106
[5] Mohn, K. G.-I., Smith, I., Sjursen, H., & Cox, R. J. (2018). Immune responses after live attenuated influenza vaccination. Human Vaccines & Immunotherapeutics, 14(3), 571–578. https://doi.org/10.1080/21645515.2017.1377376
[6] Nichol, K. L., et al. (1999). Effectiveness of live, attenuated intranasal influenza vaccine in healthy, working adults. JAMA, 282(2), 137–144. https://doi.org/10.1001/jama.282.2.137
[7] Thwaites, R. S., et al. (2023). Early mucosal events promote distinct compartmentalized antibody responses after LAIV. Nature Communications, 14, 7922. https://doi.org/10.1038/ s41467-023-43842-7
[8] Mao, T., et al. (2022). Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science, 378(6622), eabo2523. https://doi.org/10.1126/science. abo2523
[9] Vu, M. N., Pilapitiya, D., Kelly, A., Koutsakos, M., Kent, S. J., Juno, J. A., Tan, H. X., & Wheatley, A. K. (2025). Deconvolution of cargo delivery and immunogenicity following intranasal delivery of mRNA lipid nanoparticle vaccines. Molecular Therapy – Nucleic Acids, 36, 102547. https://doi.org/10.1016/ j.omtn.2025.102547
[10] Jeyanathan, M., Afkhami, S., D’Agostino, M. R., Satia, I., Fritz, D. K., Miyasaki, K., … Xing, Z. (2025). Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: An open-label, multi-arm Phase 1 clinical trial (NCT05094609). Nature Communications, 16(1), 6000. https://doi.org/10.1038/s41467-025-60726-0
[11] Chen, J., Lin, W., Yang, C., Lin, W., Cheng, X., He, H., Li, X., & Yu, J. (2025). Immunogenicity, safety, and protective efficacy of mucosal vaccines against respiratory infectious diseases: A systematic review and meta-analysis. Vaccines, 13(8), 825. https://doi.org/10.3390/vaccines13080825
[12] Knisely, J. M., et al. (2023). Mucosal vaccines for SARS- CoV-2: Scientific gaps and opportunities. npj Vaccines, 8(1), 145. https://doi.org/10.1038/s41541-023-00654-6
[13] Tobias, J., Steinberger, P., Wilkinson, J., Klais, G., Kundi, M., & Wiedermann, U. (2024). SARS-CoV-2 vaccines: The advantage of mucosal vaccine delivery and local immunity. Vaccines, 12(7), 795. https://doi.org/10.3390/vaccines12070795
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
